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a  b  s  t  r  a  c  t
The presented study had two objectives. The ﬁrst was to examine distributions of Hepatitis C
Virus (HCV) genotypes in Sindh, Pakistan, where HCV is prevalent. The other was to explore
clinically relevant relationships between the genotypes, viral load (measured by real-time
polymerase chain reaction assays) and biochemical markers. For this, 1471 HCV-infected
patients in six cities in Sindh were recruited and sampled. HCV genotype distributions varied
among the cities, but genotype 3a was most prevalent, followed by 3b, 1a and 1b (detected in
51.5,  22.7. 9.25 and 3.2% of the cases, respectively). No type-speciﬁc sequences were detected
in  serum samples from 189 (12.8%) of the 1471 patients. Frequencies of low (<200,000 IU/mL
serum), intermediate (200,000–600,000 IU/mL serum) and high (>600,000 IU/mL serum) viral
loads were respectively 45.4, 16.5 and 38.1% for patients infected with genotype 3, and 16.9,
36.9  and 46.2%, respectively, for patients with other genotypes. Infection with genotype
1a was associated with signiﬁcantly higher (p < 0.005) alanine aminotransferase, aspartate
aminotransferase and alkaline phosphatase titers than infection with genotype 3a. The
results will help in the formulation of treatment strategies.© 2016 Sociedade Brasileira de Microbiologia. Published by Elsevier Editora Ltda. This is
s arti
highest infection rate in the world, 4.5–8%.an  open acces
Introduction
Infection by the hepatitis C virus (HVC) is a serious health
issue,1 with an estimated global of prevalence of 2.35% in
2010, increasing to 2.8% in 2013, and hence >185 million
infections.2–4 The mortality rate is also very high; more
than 350,000 individuals die annually from life-threatening
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complications, which include cirrhosis.5 Countries with the
highest reported rates of HCV infection are in East Asia, Africa,
North America and Thailand.4,6,7 Pakistan has the second
8. Haider).
HCV is a single-stranded linear RNA virus with a high
mutation rate; an estimated frequency of 10−2 mutations
per nucleotide per year.9 Its genome is approximately 9.6 kb
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ab r a z i l i a n j o u r n a l o f m i c 
ong, and consists of a single open reading frame encoding a
olypeptide chain of 3000 amino acids.10 The number of rec-
gnized genotypes has recently increased from six to seven,
nd numbers of recognized subtypes has greatly expanded to
7.11
Genotypes 1, 2, and 3 are most prevalent globally,12 while
ther genotypes are limited to speciﬁc regions. HCV genotyp-
ng provides information about variability in the viral genome,
ikely disease progression and possible treatment strategies.13
he most common genotypes, collectively accounting for
pproximately 80% of the infections, in the Pakistani popu-
ation are reportedly 3a, followed by 3b and 1a.14
Early diagnosis and treatment of HCV infection mini-
ize risks of both long-term complications like ﬁbrosis and
irrhosis developing, and transmission of infection in the
ommunity.15 Further, various biochemical and molecular
arkers are now available that can be used in screening for
epatitis C infection, and for both diagnosis and monitor-
ng chronic HCV infection. To determine viremia a number
f methods are available, but quantitative polymerase chain
eaction (PCR) and branched-chain DNA (bDNA) assays are
ost widely used. Determination of viral loads is useful for
onitoring both treatment responses and relapse rates.14 In
hronically infected individuals, both viral load and HCV geno-
ype may have clinical relevance, as virus loads at the time of
iagnosis are correlated to required treatment durations.9 The
CV mortality rate is growing in Pakistan due to deﬁciencies
n both diagnosis and treatment.8
In HCV infection, the clinical ﬁndings, quantiﬁcation of
irus and genotype determination are strong predictors for
he antiviral therapy. Different studies have been conducted
xploring the clinical signiﬁcance and relationship between
iral load and genotype.16 It is essential that the method used
o quantitate viral load be unaffected by the variability of HCV.9
The present work has been conducted to document the
revalence of HCV genotypes and their association with
iremia and biochemical markers in patients from different
ities of Sindh province. Diagnosis, prognosis, interferon ther-
py, and clinical management of HCV are very poor due to
he lack of health facilities in developing countries.17 Differ-
nt studies are available, where the relationship between HCV
enotypes, viral load and different biochemical markers has
een explored in Pakistani population.8,18,19
Diagnosis, prognosis, therapy, and clinical management
f HCV are very poor due to the lack of health facilities
n developing countries.17 Accordingly, the HCV mortality
ate is growing in Pakistan due to shortcomings in both
iagnosis and treatment,8 and it is important to improve
he genotyping and quantiﬁcation of viral loads, which are
trong indicators of optimal therapies.16 Clearly, the method
sed to quantify viral load must not be affected by the
ariability of HCV.9 Further knowledge is also required of
he distributions of genotypes in the country, and their
elationships with viral loads and clinically relevant bio-
hemical markers. Several studies have explored distributions
f genotypes and viral loads in the country,8,18,19 but
igher-resolution data are required. Furthermore, as already
entioned numbers of recognized genotypes and subtypes
as greatly increased recently, and more  biomarkers are now
vailable.o l o g y 4 7 (2 0 1 6) 980–986 981
Thus, the study presented here had two objectives. The ﬁrst
was to document distributions of HCV genotypes in patients
from six cities in Sindh (the second most heavily populated
province of Pakistan). The other was to acquire more  detailed
knowledge of relationships between the genotypes and both
viral loads and biochemical markers.
Materials  and  methods
Study  area  and  subjects
The study was carried out between July 2010 and July 2013 at
Citi Lab and Research Center, Lahore. HCV-infected patients
who attended medical centers/sub-centers in six cities of
Sindh province (Shikarpur, Nawabshah, Kashmore, Kandi-
aro, Dadu, Khairpur) were recruited, following international
guidelines for human studies (The NuGO, 2007). Criteria
for inclusion were: residence in these cities; HCV-positive
results from an Enzyme Linked Immunosorbent Assay (ELISA,
see below); detection of HCV RNA in serum by reverse-
transcription polymerase chain reaction assays; and absence
of detectable infection by other viruses, e.g. hepatitis B Virus
(HBV), Hepatitis D Virus (HDV) and HIV. Patients were informed
about the study and those recruited consented to participate.
Their demographic characteristics, including age, marital sta-
tus and complications, were documented. Serum samples
were collected from all of the patients and stored at −80 ◦C
until further analysis.
ELISA  test  for  anti-HCV  antibodies
A commercial kit (3rd Generation Micro ELISA HCV Ab,
Amgenix, USA), which includes a 96-well antigen-coated
plate, was used to detect anti-HCV antibodies. Following the
manufacturer’s instructions, serum samples were individually
added to the wells, followed by horseradish peroxidase labeled
with monoclonal antibody. After ﬁve washings with phos-
phate buffered saline (PBS) incubation titers were obtained by
measuring absorbance at 450 nm using a RT-6000 microplate
reader (Rayto, Germany).
Isolation  of  HCV  RNA,  cDNA  synthesis  and  qualitative
PCR analysis  of  HCV
HCV RNA was isolated from each patient’s serum using Trizol
following instructions of the manufacturer (Invitrogen, USA),
except that the centrifugation time was reduced from 15 to
12 min. After adding TRIzol reagent RNA was extracted with
chloroform and alcohol.
HCV RNA was then detected by nested reverse-
transcription PCR using 5′ UTR primers, as previously
described by Idrees et al.8 Brieﬂy, 10 L portions of extracted
RNA were reverse-transcribed into cDNA, using maloney
murine leukemia virus reverse transcriptase (M-MLV RT, 100
units) and 1 M of downstream primer (Outer anti-sense). The
products generated from each sample were subjected to two
separate PCR ampliﬁcations, one with primer set A and the
other with primer mix  B, in 20 L reaction volumes containing
4.0 L of 5× First Strand Buffer, 1.0 L, dNTPs (10 mM),  3.0 L
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dH2O and Taq polymerase (Fermentas Life Sciences, USA).
The resulting speciﬁc HCV bands were visualized by ethidium
bromide following electrophoretic separation on 2% agarose.
Primer set A includes primers for genotypes 1a, 1b, 1c, 3a,
3c and 4, while set B includes primers for genotypes 2a, 3c,
3b, 5a, and 6a. The two  sets are grouped according to sizes
of sequences they amplify, to avoid generating products that
would migrate to similar positions during electrophoresis.
Viral  load  and  genotype  determination
HCV RNA was quantiﬁed by real-time PCR (Bio-Rad Min-
iOpticonTM, USA) using a RoboGene® Hepatitis C virus
Quantiﬁcation Kit (AJ Roboscreen GmbH, Leipzig Germany)
according to the manufacturer’s instructions.
The method described by Ohno et al. was used for the
HCV genotyping. Brieﬂy, cDNA was synthesized using 50 ng of
HCV RNA and 100 U of M-MLV  RTEs with incubation at 37 ◦C
for 50 min.20 In ﬁrst-round PCR ampliﬁcation a 470-bp region
from the HCV 5′ UTR and core region was obtained using
2 L portions of the synthesized DNA solutions. The products
were then subjected to two second round PCR ampliﬁcations
with the sets of primers (A and B) described above. Following
ampliﬁcation and electrophoretic separation, bands were
detected by ethidium bromide staining, observed under a UV
transilluminator, and HCV genotype-speciﬁc PCR bands were
identiﬁed using a 100-bp DNA ladder (Fermentas, USA).
Biochemical  markers
Clinical chemistry kits (Human, Germany) and an auto-
matic biochemistry analyzer (Micro Lab 300, Merck Germany)
were used to analyze biochemical markers such as aspar-
tate aminotransferase (AST), alanine transaminase (ALT),
-glutamyl transferase (-GT), alkaline phosphatase (ALP),
bilirubin and total protein – in the serum samples.
Statistical  analysis
The data were analyzed using the statistical package, SPSS ver-
sion 18. All presented quantitative data are means ± standard
deviations. Means of pairs of groups were compared by Inde-
pendent Sample t-tests, and ANOVA was used to compare
means of more  than two groups. p-values < 0.005 are consid-
ered signiﬁcant.
Results
We  recruited 1471 HCV-infected patients (1043 males, 428
females: male to female ratio, 2.4) from six cities of Sindh
province, the second most heavily populated province of
Pakistan. As shown in Table 1, signiﬁcant between-gender
differences (p < 0.005) were detected in prevalence of all geno-
types among the patients except 2a (p = 0.257), with male to
female ratios ranging from 1.72 for genotype 3b to 5.48 for
genotype 1a. Overall genotype 3a was most prevalent among
the patients, followed by 3b, 1a, 1b and 2a (detected in 51.5,
22.7, 9.2, 3.2 and 0.48% of the samples, respectively). No
genotypes were obtained for 12.8% of the patients (Table 1). b i o l o g y 4 7 (2 0 1 6) 980–986
Genotype 3a was most prevalent in patients from all of the
cities (Table 2), but it was 12.9% more  prevalent in patients
from Dadu (59.7%) than in those from Shikarpur (46.8%), while
genotype 3b was ca. 14% more  prevalent among patients from
Shikarpur (26%) than among patients from Kandiaro (12.2%).
HCV genotype 1a was highly prevalent among patients from
Kandiaro (19.8%), three times more  frequent than among
patients from Dadu (6.04%). Genotype 1b was most frequent in
Shikarpur (detected in 5.09% of the patients). Genotype 2a was
the least prevalent (<1%) in patients from all study areas, and
it was not detected in any patients from Dadu and Khairpur.
The patients from Dadu had the highest proportion with unde-
termined genotypes (16.1%). There were signiﬁcant (p < 0.005)
variations in prevalence of all genotypes among patients from
all six cities according to ANOVA, except for genotype 2a
(p = 0.666).
Analysis of associations between the patients’ ages
(in 10-year intervals) and HCV genotypes showed that HCV
was most frequent among individuals aged 30–40 years fol-
lowed by those aged 40–49 and 50–59 years (Table 3).
Genotype 3a was the most prevalent in all age groups.
Infection rates of genotypes 3b and 1a were respectively high-
est among the 40–49 year-olds (35.6%) and 50–59 year-olds
(12.3%). Interestingly, genotype distributions in the groups
aged 10–19 and >70 years were very similar. Following Ali et al.,
we categorized viral loads of <200,000, 200,000–600,000 and
>600,000 IU/mL as low, intermediate and high, respectively
(Table 4), and found a non-signiﬁcant association (p = 0.031)
between the load and gender.21 However, we  detected signiﬁ-
cant between-genotype differences in viral loads, as genotype
3 was associated with low HCV viral loads while the others
were associated with intermediate or high loads (Table 4).
Analysis of associations between HCV genotypes and bio-
chemical markers showed that levels of ALT, -GT and ALP
signiﬁcantly differed (p < 0.005) among patients infected with
1a, 1b, 3a and 3b genotypes, but no signiﬁcant between-
genotype differences in levels of the other biomarkers were
detected (Table 5). Genotypes 1a and 3b were respectively asso-
ciated with the highest and lowest levels of ALT, -GT and ALP
(Table 5).
Discussion
Sindh is the second most populated province of Pakistan,
with a population of 35.2 million people. Distinctive distribu-
tions of HCV genotypes have been observed geographically
and distribution changes even in different regions of the
same community.5 The HCV prevalence rate varies among
the four provinces of Pakistan in the following order: Punjab
having 6.7%, Sindh 5%, Baluchistan 1.5%, and 1.1% in Khyber
Pakhtunkhwa (KPK).22 It was reported that genotype 3 was the
predominant strain in Pakistan.7 In Punjab major prevalent
genotype was 3a, followed by genotype 1a.23 We  investi-
gated whether there are geographical differences concerning
the HCV genotypes frequencies in different cities of Sindh
and evaluated their association with viral load and serum
biomarkers Sindh is the second most populated province of
Pakistan, with a population of 35.2 million people and it has
the second highest prevalence of HCV: ca. 5%, compared to 6.7,
b r a z i l i a n j o u r n a l o f m i c r o b i o l o g y 4 7 (2 0 1 6) 980–986 983
Table 1 – Gender wise genotype distribution in HCV infected patients of Sindh (n = 1471).
Genotype Male Female p-value Total  Gender
Subtype Frequency Percentage Frequency Percentage Frequency Percentage Ratio
Genotype 1 149 14.28 34 7.94 0.001 183 12.44 4.39
1a 115 11.02 21 4.9 0.001 136 9.25 5.48
1b 34 3.26 13 3.04 0.002 47 3.2 2.62
Genotype 2 5  0.48 2  0.47 0.257 7  0.48 2.5
2a 5 0.48 2  0.47 0.257 7 0.48 2.5
Genotype 3 750 71.91 342 79.9 0.001 1092 74.24 2.2
3a 539 51.67 219 51.16 0.001 758 51.53 2.47
3b 211 20.23 123 28.74 0.001 334 22.71 1.72
Undetermined 139 13.33 50 11.69 0.001 189 12.84 2.78
Total 1043 428 1471
p < 0.005 was considered as signiﬁcant.
Table 2 – Distribution of genotypes of HCV isolates in different cities of Sindh (n = 1471).
Genotypes/cities 1a 1b 2a 3a 3b UN Total
Shikarpur 38 (9.22) 21 (5.09) 1 (0.24) 193 (46.84) 107 (25.97) 52 (12.63) 412 (28)
Nawabshah 33 (8.29) 12 (3.01) 3 (0.75) 192 (48.24) 101 (25.38) 57 (14.32) 398 (27)
Kashmore 20 (8.10) 06 (2.43) 2.0 (0.80) 142 (57.49) 53 (21.46) 24 (9.71) 247 (16.8)
Kandiaro 26(19.84) 03 (2.29) 01 (0.76) 73 (55.72) 16 (12.21) 12 (9.15) 131 (8.9)
Dadu 9.0 (6.04) 01 (0.67) 0 (0) 89 (59.73) 26 (17.45) 24 (16.1) 149 (10.1)
Khairpur 10 (7.46) 04 (2.98) 0 (0) 69 (51.49) 31 (23.13) 20 (14.93) 134 (9.2)
p-value 0.001 0.001 0.666 0.001 0.001 0.001
Note:  Percentages (%) in parenthesis, UN, undetermined/untypable, p < 0.005 was considered as signiﬁcant.
Table 3 – Age wise HCV genotype/subtype distribution in Sindh (n = 1471).
Age groups (years) 1a 1b 2a 3a 3b UN Total
10–19 2 (8.0) 0 (0) 0 (0) 17 (68.0) 05 (20.0) 01 (4.0) 25
20–29 11 (7.05) 01 (0.64) 03 (1.92) 76 (48.72) 39 (25) 26 (16.67) 156
30–39 39 (7.54) 28 (5.4) 01 (0.19) 263 (50.87) 122 (23.6) 64 (12.37) 517
40–49 34 (10.53) 11 (3.40) 0 (0) 119 (36.84) 115 (35.60) 44 (13.62) 323
50–59 39 (12.30) 3 (0.95) 02 (0.63) 206 (64.98) 28 (8.83) 39 (12.3) 317
60–69 10 (9.0) 4 (3.60) 01 (0.90) 62 (55.86) 22 (19.81) 12 (10.8) 111


















tNote:  Percentages (%) in parenthesis, UN, undetermined.
.5 and 1.1% in Punjab, Baluchistan and Khyber Pakhtunkhwa,
espectively.22 Clear variations in geographical distributions
f HCV genotypes have been observed, even within regions
f the country.5 However, genotype 3 is the predominant
train in Pakistan, according to Rasheed et al.,7 and 3a is the
ost prevalent in Punjab, followed by 1a, according to Aziz
t al.23 To acquire higher-resolution data and explore associ-
tions between genotypes and clinically relevant biomarkers
e investigated possible geographical variations in frequen-
ies of HCV genotypes among cities in Sindh, then evaluated
heir associations with viral loads and a set of serum biomark-
rs.
We found that genotype 3 accounts for more  than 70%
f HCV infections in Sindh (at least amongst our patients),
nd that genotype 3a is most prevalent, followed by 3b, 1b
nd 2a (accounting for 51.5, 22.7, 9.25, 3.2 and 0.48% of the
xamined cases, respectively). These ﬁndings are consistent
ith previously reported patterns of HCV variants’ distribu-
ions in Pakistan,21,24 although genotype 4a is emerging in thecountry, according to Mahmood et al.25 We  did not detect
genotype 5 or 6 in any of the analyzed samples.
Diverse distributions of HCV variants have been detected
across the world, and we  found signiﬁcant variations in popu-
lations from the six cities of Sindh. Genotypes 3a and 3b were
most frequent in patients from all of the cities, followed by 1a
and 1b. Similar patterns have been widely observed in both
Pakistan and neighboring countries,9 including Bangladesh,26
India,27 Nepal28 and Iran.29 However, the incidence of every
genotype varied signiﬁcantly, although the infection rate of
genotype 2a was consistently very low (accounting for <1% of
cases). Genotype 3a was ca. 12.9% more  frequent in patients
from Dadu (59.7%) than in patients from Shikarpur (47%), who
had a ca. 14% higher frequency of infection by genotype 3b
than patients from Kandiaro (26% and 12.2%, respectively).
The prevalence of genotype 1a was highest among patients
from Kandiaro (19.84%).
The differences in distributions of HCV genotypes are likely
to be due to several factors, including secular changes in HCV
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Table 4 – HCV viral load categories and their distribution by gender and genotypes in different cities of Sindh.
HCV viral load
<200,000 200,000–600,000 >600,000
IU/mL (%) IU/mL (%) IU/mL (%) p-value
Gender
Males 387 37.1 215 20.61 441 42.28
Females 173 40.42 105 24.53 150 35.04 0.031
Sindh
Genotype3 496 45.42 180 16.48 416 38.1
Others 64 16.89 140 36.94 175 46.17 0.001
Shikarpur
Genotype3 103 34.33 34 11.33 163 54.33
Others 16 14.29 43  38.39 53 47.32 0.001
Nawabshah
Genotype3 157 53.58 47 16.04 89 30.38
Others 18 17.14 37 35.24 50 47.62 0.001
Kashmore
Genotype3 90 46.15 43 22.05 62 31.79
Others 12 23.07 21 40.38 19 36.54 0.004
Kandiaro
Genotype3 29 23.58 27  30.34 33 37.07
Others 7 16.66 21 50 14 33.33 0.056
Dadu
Genotype3 60 52.17 16 13.91 39 33.91
Others 4 11.76 10 29.41 20 58.82 0.001
Khairpur
Genotype3 57 57 13 13 30 30
Others 7 20.59 8 23.53 19 55.88 0.001
 all sNote:  Percentages (%), p < 0.005 was considered as signiﬁcant (others =
distribution and associated risk factors. In Brazil, signiﬁcant
variations (p = 0.001) in frequencies of genotypes among areas
have been found in two studies, but both found that geno-
type 1a was consistently predominant.30,31 This pattern of
distribution is similar to the present study. Age-related anal-
ysis of infections revealed that the most common genotype
was 3a variants among all age groups as reported by Lazo
et al.12 In agreement with previous reports, the highest HCV
prevalence was reported among individuals between 30 and 40
years.23 Our results contradict with Nafees et al., who reported
that older females (41–50 years) had higher HCV prevalence
than males. Genotype 3b showed the highest infection rate
(35.6%) in age group 40–49 years.32 It has been reported from
Table 5 – Association of HCV genotypes with biomarkers in Sin
Genotype n (%) ALT AST -GT 
1a 136 (9.25) 121.3 ± 11.2 91.3 ± 8.6 97.3 ± 8.9 
1b 47 (3.20) 90.4 ± 8.8 80.2 ± 8.0 89.4 ± 8.7 
3a 758 (51.53) 69.2 ± 5.7 61.7 ± 4.8 62.1 ± 5.9 
3b 33.4 (22.71) 87.1 ± 7.6 79.4 ± 6.4 84.3 ± 7.1 
p-value – 0.001 0.0264 0.001 
Normal values: alanine amino transferase (ALT) < 40 U/L, aspartate ami
gamma-glutamyl transferase (GT) < 40 U/L, Bilirubin < 1 mg/dL, T. Protein
p > 0.005.tudied genotypes except 3).
China that males have persistent elevated HCV RNA levels and
are at higher risk as compared to females.33 In contrast, we
found that that the most common genotype was 3a, among
all age groups of our patients from Sindh, as also recorded
by Lazo et al.12 In agreement with Aziz et al., we  found that
HCV was most prevalent among individuals between 30 and
40 years old, but our results conﬂict with ﬁndings by Nafees
et al., that HCV was more  prevalent among 41–50 year-old
females than among males of this age.23,32 The most com-
mon  genotype in this age group (accounting for 35.6% of cases)
was 3b. Our results also conﬂict with ﬁndings that infected
males have persistently higher HCV RNA levels than infected
females, and are at higher risk,33 as we  found no clear or
dh Province.
ALP Bilirubin T. Protein Albumin
483.2 ± 11.2 2.26 ± 0.71 9.04 ± 0.51 3.26 ± 0.28
442.1 ± 10.5 1.98 ± 0.37 8.95 ± 0.61 3.71 ± 0.33
390.8 ± 8.5 1.78 ± 0.43 8.61 ± 0.31 3.64 ± 0.41
425.3 ± 10.6 1.94 ± 0.0.46 9.26 ± 0.0.53 3.12 ± 0.11
0.001 0.418 0.321 0.145
no transferase (AST) < 40 U/L, alkaline phosphatase (ALP) < 306 U/L,
: 6–8.5 g/dL, Albumin: 3.4–4.8 g/dL, Signiﬁcant p < 0.005, Insigniﬁcant
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igniﬁcant (p < 0.005) differences in viral loads between both
enders.
However, we  detected signiﬁcant differences in associ-
ted viral loads between genotype 3 and the others. The
ercentage of patients with a low load (<200,000 IU/mL)
as highest (45.4%) among those infected with genotype 3,
hile 36.9% and 46.1% of patients with other genotypes had
ntermediate (>200,000 IU/mL and <600,000 IU/mL) and high
>600,000 IU/mL) viral loads, respectively. Similarly, Rong et al.,
eported that genotype 1 (included in other genotypes in this
tudy) was associated with higher HCV RNA levels than geno-
ype 3.34
Relationships between the genotypes and serum biomark-
rs are ambivalent, possibly due to the heterogeneity in HCV
enetic variants, according to Al-Swaff.35 However, Ijaz et al.,
etected relationships between HCV genotypes and serum
evels of both ALT and ALP.18 Extending these results, we found
hat genotype 1a was associated with consistently and signiﬁ-
antly (p < 0.005) higher serum levels of ALT, ALP and -GT than
enotype 3a.
In conclusion, the most prevalent HCV genotypes in Sindhi
atients appear to be 3a followed by 3b, 1a and 1b. However,
here are signiﬁcant differences within the region, for exam-
le 3a is more  prevalent in patients from Dadu than in those
rom the other cities. Genotype 3 is associated with the low-
st viral loads, and infection by genotype 1a is associated with
igher levels of the serum biomarkers. More  importantly, the
esults reveal strong within-region variations in genotype fre-
uencies, associated viral loads and biomarker levels. Hence,
hey highlight the need for high-resolution analyses of these
ariables to facilitate formulation of robust therapeutic strate-
ies.
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